Dr. Mariya Rozenblit, MD
Claim this profileSmilow Cancer Hospital-Derby Care Center
Studies Breast Cancer
Studies Breast cancer
4 reported clinical trials
13 drugs studied
Area of expertise
1Breast Cancer
HER2 negative
ER positive
PR positive
2Breast Cancer
HER2 negative
ER positive
PR positive
Affiliated Hospitals
Clinical Trials Mariya Rozenblit, MD is currently running
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Niraparib + Dostarlimab
for Breast Cancer
This research study involves pre-operative therapy that is specifically targeted for breast cancer in individuals with BRCA and PALB2 mutations. The names of the study drugs involved in this study are: * Niraparib (Zejula) * Dostarlimab
Recruiting1 award Phase 211 criteria
More about Mariya Rozenblit, MD
Clinical Trial Related1 year of experience running clinical trials · Led 4 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Mariya Rozenblit, MD has experience with
- DiviTum-TKa
- Biopsy
- Biospecimen Collection
- Patient Observation
- Pembrolizumab
- Quality-of-Life Assessment
Breakdown of trials Mariya Rozenblit, MD has run
Breast Cancer
Breast cancer
PALB2 Mutation
BRCA1 Mutation
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Mariya Rozenblit, MD specialize in?
Mariya Rozenblit, MD focuses on Breast Cancer and Breast cancer. In particular, much of their work with Breast Cancer has involved HER2 negative patients, or patients who are ER positive.
Is Mariya Rozenblit, MD currently recruiting for clinical trials?
Yes, Mariya Rozenblit, MD is currently recruiting for 4 clinical trials in Derby Connecticut. If you're interested in participating, you should apply.
Are there any treatments that Mariya Rozenblit, MD has studied deeply?
Yes, Mariya Rozenblit, MD has studied treatments such as DiviTum-TKa, Biopsy, Biospecimen Collection.
What is the best way to schedule an appointment with Mariya Rozenblit, MD?
Apply for one of the trials that Mariya Rozenblit, MD is conducting.
What is the office address of Mariya Rozenblit, MD?
The office of Mariya Rozenblit, MD is located at: Smilow Cancer Hospital-Derby Care Center, Derby, Connecticut 06418 United States. This is the address for their practice at the Smilow Cancer Hospital-Derby Care Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.